1.59
-0.01 (-0.63%)
| Previous Close | 1.60 |
| Open | 1.59 |
| Volume | 27,567 |
| Avg. Volume (3M) | 102,983 |
| Market Cap | 67,369,888 |
| Price / Earnings (Forward) | 11.70 |
| Price / Sales | 11.46 |
| Price / Book | 1.05 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -749.51% |
| Diluted EPS (TTM) | -0.770 |
| Quarterly Revenue Growth (YOY) | 1.20% |
| Total Debt/Equity (MRQ) | 8.19% |
| Current Ratio (MRQ) | 4.36 |
| Operating Cash Flow (TTM) | -25.60 M |
| Levered Free Cash Flow (TTM) | -13.62 M |
| Return on Assets (TTM) | -58.16% |
| Return on Equity (TTM) | -113.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | InspireMD Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 1.5 |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 30.14% |
| % Held by Institutions | 42.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rosalind Advisors, Inc. | 30 Sep 2025 | 3,905,743 |
| Velan Capital Investment Management Lp | 30 Sep 2025 | 2,143,698 |
| Pura Vida Investments, Llc | 30 Sep 2025 | 450,517 |
| Huntleigh Advisors, Inc. | 30 Sep 2025 | 264,004 |
| Affiance Financial, Llc | 30 Sep 2025 | 250,370 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BERMAN MICHAEL | 1.59 | - | 88,053 | 140,004 |
| COHEN RAYMOND W | 1.59 | - | 44,030 | 70,008 |
| DEAREN DANNY L. | 1.59 | - | 44,030 | 70,008 |
| GLEASON SHANE THOMAS | 1.59 | - | 453,390 | 720,890 |
| LAWLESS MICHAEL A | 1.59 | - | 226,695 | 360,445 |
| ROUBIN GARY S | 1.59 | - | 88,053 | 140,004 |
| SLOSMAN MARVIN | 1.59 | - | 1,114,792 | 1,772,519 |
| STUKA PAUL | 1.59 | - | 132,076 | 210,001 |
| TOMMASOLI ANDREA | 1.59 | - | 226,695 | 360,445 |
| WARD SCOTT R. | 1.59 | - | 88,053 | 140,004 |
| Aggregate Net Quantity | 2,505,867 | |||
| Aggregate Net Value ($) | 3,984,329 | |||
| Aggregate Avg. Buy ($) | 1.59 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BERMAN MICHAEL | Director | 14 Jan 2026 | Acquired (+) | 88,053 | 1.59 | 140,004 |
| COHEN RAYMOND W | Director | 14 Jan 2026 | Acquired (+) | 44,030 | 1.59 | 70,008 |
| DEAREN DANNY L. | Director | 14 Jan 2026 | Acquired (+) | 44,030 | 1.59 | 70,008 |
| GLEASON SHANE THOMAS | Officer | 14 Jan 2026 | Acquired (+) | 453,390 | 1.59 | 720,890 |
| LAWLESS MICHAEL A | Officer | 14 Jan 2026 | Acquired (+) | 226,695 | 1.59 | 360,445 |
| ROUBIN GARY S | Director | 14 Jan 2026 | Acquired (+) | 88,053 | 1.59 | 140,004 |
| SLOSMAN MARVIN | Officer | 14 Jan 2026 | Acquired (+) | 1,114,792 | 1.59 | 1,772,519 |
| STUKA PAUL | Director | 14 Jan 2026 | Acquired (+) | 132,076 | 1.59 | 210,001 |
| TOMMASOLI ANDREA | Officer | 14 Jan 2026 | Acquired (+) | 226,695 | 1.59 | 360,445 |
| WARD SCOTT R. | Director | 14 Jan 2026 | Acquired (+) | 88,053 | 1.59 | 140,004 |
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) |
| 24 Nov 2025 | Announcement | Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting |
| 21 Nov 2025 | Announcement | InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 19 Nov 2025 | Announcement | InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference |
| 04 Nov 2025 | Announcement | InspireMD Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |